Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects

British Journal of Pharmacology

Volumn 159, Issue 6, 2010, Pages 1201-1210

  Ueda, M ^a,b   Iida, Y ^c   Tominaga, A ^b   Yoneyama, T ^b   Ogawa, M ^d   Magata, Y ^d   Nishimura, H ^e   Kuge, Y ^b,f   Saji, H ^b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f HOKKAIDO UNIVERSITY   (Japan)

Author keywords

5IA; Anti allodynic effect; Neuropathic pain; Nicotinic acetylcholine receptor; Thalamus; Ventral posterolateral thalamic nucleus

Indexed keywords

5 IODO 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 5 IODO 3 (2 AZETIDINYLMETHOXY)PYRIDINE I 125; ANALGESIC AGENT; MECAMYLAMINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HYPERALGESIA; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; THALAMUS NUCLEUS;

ANIMALS; AUTORADIOGRAPHY; AZETIDINES; DISEASE MODELS, ANIMAL; IODINE RADIOISOTOPES; MALE; NICOTINIC AGONISTS; PAIN; PAIN THRESHOLD; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SCIATIC NEUROPATHY; VENTRAL THALAMIC NUCLEI;

EID: 77949416116     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00613.x     Document Type: Article

References (44)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ et al. (1998a). ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther 285: 787-794.
3. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS et al. (1998b). Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 279: 77-81.
4. Bannon AW, Decker MW, Kim DJ, Campbell JE, Arneric SP (1998c). ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain. Brain Res 801: 158-163.
5. Bitner RS, Nikkel AL, Curzon P, Arneric SP, Bannon AW, Decker MW (1998). Role of the nucleus raphe magnus in antinociception produced by ABT-594: immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. J Neurosci 18: 5426-5432.
6. Bitner RS, Nikkel AL, Curzon P, Donnelly-Roberts DL, Puttfarcken PS, Namovic M et al. (2000). Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res 871: 66-74.
7. Brasic JR, Zhou Y, Musachio JL, Hilton J, Fan H, Crabb A et al. (2009). Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers. Synapse 63: 339-358.
8. Chen SR, Pan HL (2003). Up-regulation of spinal muscarinic receptors and increased antinociceptive effect of intrathecal muscarine in diabetic rats. J Pharmacol Exp Ther 307: 676-681.
9. Curzon P, Nikkel AL, Bannon AW, Arneric SP, Decker MW (1998). Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats. J Pharmacol Exp Ther 287: 847-853.
10. Decker MW, Curzon P, Holladay MW, Nikkel AL, Bitner RS, Bannon AW et al. (1998). The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. J Physiol Paris 92: 221-224.
11. Decker MW, Rueter LE, Bitner RS (2004). Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Curr Top Med Chem 4: 369-384.
12. Derbyshire SW, Jones AK, Gyulai F, Clark S, Townsend D, Firestone LL (1997). Pain processing during three levels of noxious stimulation produces differential patterns of central activity. Pain 73: 431-445.
13. Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE et al. (1998). ABT-594 [(R)-5-(2-azetidinylmethoxy)-2- chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. J Pharmacol Exp Ther 285: 777-786.
14. Doura MB, Gold AB, Keller AB, Perry DC (2008). Adult and periadolescent rats differ in expression of nicotinic cholinergic receptor subtypes and in the response of these subtypes to chronic nicotine exposure. Brain Res 1215: 40-52.
15. Fukui M, Nakagawa T, Minami M, Satoh M (2001). Antinociceptive effects of intracerebroventricularly administered P2 purinoceptor agonists in the rat. Eur J Pharmacol 419: 25-31.
16. Gybels J (2001). Thalamic stimulation in neuropathic pain: 27 years later. Acta Neurol Belg 101: 65-71.
17. Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW et al. (1998). Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J Med Chem 41: 407-412.
18. Itier V, Schonbachler R, Tribollet E, Honer M, Prinz K, Marguerat A et al. (2004). A-186253, a specific antagonist of the alpha 4 beta 2 nAChRs: its properties and potential to study brain nicotinic acetylcholine receptors. Neuropharmacology 47: 538-557.
19. Iwamoto ET, Marion L (1993). Adrenergic, serotonergic and cholinergic components of nicotinic antinociception in rats. J Pharmacol Exp Ther 265: 777-789.
20. Jain KK (2004). Modulators of nicotinic acetylcholine receptors as analgesics. Curr Opin Investig Drugs 5: 76-81.
21. Jensen AA, Frolund B, Liljefors T, Krogsgaard-Larsen P (2005). Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem 48: 4705-4745.
22. Kanegawa N, Kiyono Y, Kimura H, Sugita T, Kajiyama S, Kawashima H et al. (2006). Synthesis and evaluation of radioiodinated (S,S)-2-(alpha-(2- iodophenoxy)benzyl)morpholine for imaging brain norepinephrine transporter. Eur J Nucl Med Mol Imaging 33: 639-647.
23. Kupers RC, Gybels JM (1993). Electrical stimulation of the ventroposterolateral thalamic nucleus (VPL) reduces mechanical allodynia in a rat model of neuropathic pain. Neurosci Lett 150: 95-98.
24. 123I-5IA SPECT. J Nucl Med 45: 1458-1470.
25. Mamede M, Ishizu K, Ueda M, Mukai T, Iida Y, Kawashima H et al. (2007). Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. J Nucl Med 48: 1829-1835.
26. Marcil J, Walczak JS, Guindon J, Ngoc AH, Lu S, Beaulieu P (2006). Antinociceptive effects of tetrodotoxin (TTX) in rodents. Br J Anaesth 96: 761-768.
27. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove d'Exaerde A et al. (1999). Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398: 805-810.
28. Mogg AJ, Jones FA, Pullar IA, Sharples CG, Wonnacott S (2004). Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380. Neuropharmacology 47: 848-859.
29. Mukhin AG, Gundisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS et al. (2000). 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 57: 642-669.
30. Oishi N, Hashikawa K, Yoshida H, Ishizu K, Ueda M, Kawashima H et al. (2007). Quantification of nicotinic acetylcholine receptors in Parkinson's disease with (123)I-5IA SPECT. J Neurol Sci 256: 52-60.
31. Okada M, Nakagawa T, Minami M, Satoh M (2002). Analgesic effects of intrathecal administration of P2Y nucleotide receptor agonists UTP and UDP in normal and neuropathic pain model rats. J Pharmacol Exp Ther 303: 66-73.
32. Paxinos G, Watson C (2005). The Rat Brain in Stereotaxic Coordinates, 5th edn. Elsevier Academic Press: San Diego, CA.
33. Perry DC, Xiao Y, Nguyen HN, Musachio JL, Davila-Garcia MI, Kellar KJ (2002). Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. J Neurochem 82: 468-481.
34. Perry DC, Mao D, Gold AB, McIntosh JM, Pezzullo JC, Kellar KJ (2007). Chronic nicotine differentially regulates alpha6- and beta3-containing nicotinic cholinergic receptors in rat brain. J Pharmacol Exp Ther 322: 306-315.
35. Saji H, Ogawa M, Ueda M, Iida Y, Magata Y, Tominaga A et al. (2002). Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy) pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Ann Nucl Med 16: 189-200.
36. Seltzer Z, Dubner R, Shir Y (1990). A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43: 205-218.
37. Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J (2001). Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415: R5-R7.
38. Sindrup SH, Jensen TS (1999). Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83: 389-400.
39. 3H]tiagabine (NNC 05-328) to the GABA uptake carrier. Brain Res 647: 231-241.
40. Tanaka K, Fukuuchi Y, Gomi S, Takashima S, Mihara B, Shirai T et al. (1993). Reduction in second-messenger ligand binding sites after brain ischemia - autoradiographic Bmax and Kd determinations using digital image analysis. Brain Res Bull 32: 49-56.
41. Ueda M, Iida Y, Kitamura Y, Kawashima H, Ogawa M, Magata Y et al. (2008). 5-Iodo-A-85380, a specific ligand for alpha4beta2 nicotinic acetylcholine receptors, prevents glutamate neurotoxicity in rat cortical cultured neurons. Brain Res 1199: 46-52.
42. 123I]Iodo-A-85380: assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. Ann Nucl Med 18: 337-344.
43. Vaupel DB, Tella SR, Huso DL, Mukhin AG, Baum I, Wagner VO et al. (2003). Pharmacology, toxicology, and radiation dosimetry evaluation of [I-123]5-I-a-85380, a radioligand for in vivo imaging of cerebral neuronal nicotinic acetylcholine receptors in humans. Drug Dev Res 58: 149-168.
44. Yasuda T, Miki S, Yoshinaga N, Senba E (2005). Effects of amitriptyline and gabapentin on bilateral hyperalgesia observed in an animal model of unilateral axotomy. Pain 115: 161-170.